The new three-year pricing initiative for generic drugs will come into effect on October 1, 2023.
The agreement between the pan-Canadian Pharmaceutical Alliance (pCPA) and the Canadian Generic Pharmaceutical Association (CGPA) builds upon the successes achieved to date with the pan-Canadian Generic Tiered Pricing Framework (TPF) and the pan-Canadian molecules.
pan-Canadian Pharmaceutical Alliance
Conducting collective expert-informed negotiations for drugs.
What's New at the pCPA
The pan-Canadian Pharmaceutical Alliance’s (pCPA) Board of Directors is excited to announce that Douglas Clark will become the first CEO of the newly incorporated organization, effective September 11, 2023
The pan-Canadian Pharmaceutical Alliance (pCPA) is an independent organization whose membership includes the provincial, territorial and federal governments. Member jurisdictions collaborate on a range of public drug plan initiatives to increase and manage access to clinically effective and affordable drug treatments.
One of the pCPA’s key roles is to conduct joint negotiations for brand name and generic drugs in Canada in order to achieve greater value for publicly funded drug programs and patients through its combined negotiating power. Its objectives are to:
- Increase access to clinically relevant and cost-effective treatments
- Achieve consistent and lower drug costs
- Improve consistency in funding decisions
- Reduce duplication and optimize resource utilization
Member Jurisdictions
The pCPA member jurisdictions include public drug plans from:
